Treatment of mammalian myocardium with morphogen locally, or with morphogenically-treated myogenic precursor cells
CA 2275436 A1 · Owner: Cohen, Charles M. · Inventors: Cohen, Charles M.; Sampath, Kuber T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides methods for the treatment and pharmaceuticals , for use in the treatment of mammalian subjects at risk of, or afflicted with loss of or damage to myocardial tissue. The methods involve the administration of certain morphogens, inducers of those morphogens agonists of the , corresponding morphogen receptors or small molecule morphogenic activators or implantation of cells induced with those agents. The morphogens useful in the invention include OP1, CBMP-2A (BMP-2) CBMP-2B (BMP-4), and other members , of the morphogens family of the TGF.beta. superfamily of growth and differentiation factors.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 19, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 19, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 19, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.